Charles J. Casamento
CIK: 0001117167
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jul 31, 2026ETON
Eton Pharmaceuticals, Inc.
Award(A)DirectCommon Stock
10K shares- - Jan 12, 2026ETON
Eton Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
7.8K shares- - Jan 12, 2026ETON
Eton Pharmaceuticals, Inc.
Award(A)DirectEmployee Stock Option (Right to Buy)
12.2K shares- - Dec 12, 2025RLMD
RELMADA THERAPEUTICS, INC.
Award(A)DirectStock Appreciation Rights
164K shares- - Sep 4, 2025GTBP
GT Biopharma, Inc.
Award(A)DirectOption to purchase Common Stock
62.5K shares- - Jun 26, 2025RLMD
RELMADA THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
100K shares- - Jan 3, 2025ETON
Eton Pharmaceuticals, Inc.
Award(A)DirectEmployee Stock Option (Right to Buy)
25K shares- - Oct 22, 2024RLMD
RELMADA THERAPEUTICS, INC.
Gift(G)Direct13K shares- - Sep 9, 2024RLMD
RELMADA THERAPEUTICS, INC.
Purchase(P)Direct13K shares at avg. $2.56$33K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 31, 2026 |  ETON Eton Pharmaceuticals, Inc. | Award(A) Common Stock | 10,000 | - | - | Direct |
| Jan 12, 2026 | ETON Eton Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 7,757 | - | - | Direct |
| Jan 12, 2026 | ETON Eton Pharmaceuticals, Inc. | Award(A) Employee Stock Option (Right to Buy) | 12,196 | - | - | Direct |
| Dec 12, 2025 |  RLMD RELMADA THERAPEUTICS, INC. | Award(A) Stock Appreciation Rights | 164,000 | - | - | Direct |
| Sep 4, 2025 |  GTBP GT Biopharma, Inc. | Award(A) Option to purchase Common Stock | 62,500 | - | - | Direct |
| Jun 26, 2025 | RLMD RELMADA THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 100,000 | - | - | Direct |
| Jan 3, 2025 | ETON Eton Pharmaceuticals, Inc. | Award(A) Employee Stock Option (Right to Buy) | 25,000 | - | - | Direct |
| Oct 22, 2024 | RLMD RELMADA THERAPEUTICS, INC. | Gift(G) | 13,000 | - | $0 | Direct |
| Sep 9, 2024 | RLMD RELMADA THERAPEUTICS, INC. | Purchase(P) | 13,000 | $2.56 | $33,280 | Direct |
1-9 of 9 transactions
About CASAMENTO CHARLES J
CASAMENTO CHARLES J (SEC CIK 0001117167) files insider reports with the SEC as Director of Eton Pharmaceuticals, Inc. (ETON), Director of RELMADA THERAPEUTICS, INC. (RLMD) and Director of GT Biopharma, Inc. (GTBP).
Signal8 holds 8 ownership filings by CASAMENTO CHARLES J, all Form 4s, filed between Sep 11, 2024 and Aug 4, 2026. Those filings report 9 transactions, from Sep 9, 2024 to Jul 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on CASAMENTO CHARLES J's filings is in DEERPARK, IL.
Recent filings by CASAMENTO CHARLES J
- Jul 31, 2026: Grant or award of ETON derivative securities (Form 4, code A).
- Jan 12, 2026: Grants or awards of ETON derivative securities (2 lines, Form 4, code A).
- Dec 12, 2025: Grant or award of RLMD derivative securities (Form 4, code A).
- Sep 4, 2025: Grant or award of GTBP derivative securities (Form 4, code A).
- Jun 26, 2025: Grant or award of RLMD derivative securities (Form 4, code A).
Other insiders filing for Eton Pharmaceuticals, Inc. (ETON)
- Krempa David, Chief Business Officer
- MAIER PAUL V, Director
- BRYNJELSEN SEAN, President & CEO
- Radosavljevic Danka, Chief Operating Officer
- Matthews Judith M., Chief Financial Officer
- Erdogan-Trinkaus Ipek, Chief Commercial Officer